Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Transcatheter Tricuspid Valve Intervention: Current Perspective
Author(s): Trevor J Simard , Mackram F Eleid Added: 2 years ago

Intervention
Transcatheter Tricuspid Valve Replacement
Author(s): Muhammad Asim Shabbir , Pradeep Yadav , Nidhish Tiwari , et al Added: 8 months ago

Imaging & Diagnostics

Intervention
Transcatheter Therapies for Tricuspid Valve Repair and Replacement
Author(s): Kusha Rahgozar , Sharon Bruoha , Edwin C Ho , et al Added: 2 years ago

Intervention
Transcatheter Edge-to-edge Repair of Severe Tricuspid Regurgitation
Author(s): Shu-I Lin , Mizuki Miura , Francesco Maisano , et al Added: 3 years ago
Moderate-to-severe tricuspid regurgitation (TR) is estimated to affect more than 1.6 million people in the US. However, fewer than 8,000 tricuspid valve operations are performed each year.1,2 There is clearly an unmet need for a tricuspid valve (TV) intervention. There has been rapid development in the field of transcatheter aortic and mitral valve interventions and percutaneous management of… View more

Vascular Disease and Surgery

Intervention
Echocardiography in the Evaluation of the Right Heart
Author(s): Angelos Tsipis , Evdokia Petropoulou Added: 2 years ago

Imaging & Diagnostics

Heart Failure
TRISCEND Study: 6Mo Outcomes Show TR Reduction in Majority of Patients
Author(s): Susheel Kodali Added: 2 years ago
Dr Susheel Kodali (Columbia University Medical Center, New York, NY, US) discusses the six-month outcomes of the TRISCEND study.Originally presented at TCT 2021, this is a randomized multicenter controlled trial aiming to evaluate the safety and effectiveness of the EVOQUE tricuspid valve replacement system. At 6 months, the results suggest positive outcomes, with a reduction in tricuspid… View more

Intervention
ACC 21: 30-day Results of the TRISCEND Study
Author(s): Susheel Kodali Added: 2 years ago
In this interview, Dr Susheel Kodali (Columbia University Medical Center, New York, US) discusses the 30-day results of the TRISCEND trial. He details the key findings of the study so far, and the next steps to be taken.Thismulti-centre, prospective, single-arm study evaluates the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System Questions:
 1.What is the TRISCEND… View more

Intervention
TCT 23: Late-Breaking Clinical Trials Revealed
Added: 6 months ago Source:  Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in… View more
Author(s): Katrina Mountfort Added: 3 years ago
The growing epidemic of cardiovascular disease, together with an ageing population represents a substantial clinical challenge that stretches healthcare budgets. There is an urgent need for both interventions focused on prevention and treatment innovations. In two sessions of presentations at EuroPCR on the 20th May 2014 in Paris, companies presented their latest innovations. The aim of these… View more

Heart Failure

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 5 months ago
What are the top late-breaking trials from #TCT2023? TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference. Dive into this practical and engaging discussion and learn more about the… View more

Intervention